neck

Alfuzosin hydrochloride (Alfuzosin HCl) is an α1 adrenergic receptor antagonist. It applies to treat benign prostatic hyperplasia (BPH).

LGK974 (NVP-LGK974) is an effective and selective PORCN inhibitor and inhibits Wnt signaling (IC50: 0.4 nM) in TM3 cells. It has been used in trials studying the treatment of Metastatic Colorectal Cancer and Squamous Cell Carcinoma, Head And Neck.

Luminespib (VER-52296) is an HSP90 inhibitor that inhibits HSP90α and HSP90β (IC50=7.8 21 nM). Luminespib has antitumor activity and is used in studies of head and neck tumors, among others.

NCGC00262650 is an inhibitor of AMA1-RON2 interaction and c-Src tyrosine kinase activity.

Borofalan(10B) (L-4-Boronophenylalanine) echibits antineoplastic effects. Borofalan can be used in studies on recurrent or locally advanced head and neck cancer.

Segetalin B is a natural product from Vaccaria segetalis (Neck.) Garcke, has estrogen-like activity.

KP372-1 is an Akt inhibitor that blocks signaling through the PI3K pathway, inhibiting cell proliferation while inducing apoptosis and anoikis in squamous cell carcinoma of the head and neck.

Monalizumab is a novel immune checkpoint inhibitor targeting natural killer cell population 2A (NKG2A). Monalizumab is a humanized monoclonal antibody against NKG2A that induces IFN-γ production, thereby activating natural killer cell function. Monalizumab has antitumor activity and can be used to study neck squamous cell carcinoma (HNSCC).

Petosemtamab (MCLA 158) is a highly potent monoclonal antibody against EGFR (Kd: 0.22 nM) and LGR5 (Kd: 0.86 nM). Petosemtamab promotes EGFR signaling disruption and receptor breakdown in LGR5+ cancer cells. Petosemtamab can be used in the study of solid tumors such as head and neck squamous cell carcinoma (HNSCC) and metastatic colorectal cancer (CRC).

Alfuzosin (SL 77499) is an orally available, competitive α1-adrenoceptor antagonist.Alfuzosin induces smooth muscle relaxation in the bladder neck and prostate.Alfuzosin has been used to study benign prostatic hypertrophy, lower urinary tract symptoms (LUTS), and ejaculatory dysfunction (EjD).

Temoporfin used in photodynamic therapy for the treatment of squamous cell carcinoma of the head and neck.

NR2F1 agonist 1, a specific nuclear receptor NR2F1 activator, initiates dormancy programs in cancer cells by upregulating NR2F1 and its target genes controlling dormancy. This compound promotes neural crest-like features and suppresses growth in head and neck squamous cell carcinoma (HNSCC) through NR2F1 activation. Moreover, NR2F1 agonist 1 demonstrates tumor growth inhibition in a mouse primary tumor model.

Amethopterin is a chemotherapy drug and immune system inhibitor used to treat cancers of the blood, bone, lung, breast, head, and neck. In addition, it can treat rheumatoid arthritis and psoriasis.

Botulinum toxin type B, an antigen-specific exotoxin produced by the anaerobic bacterium Clostridium botulinum, is utilized in the study of neck dystonia. It inhibits the release of Acetylcholine from the neuromuscular junction, causing relaxation paralysis or muscle weakening in the targeted muscle [1].

C24 dihydro Ceramide is a sphingolipid that has been found in the stratum corneum of human skin.[1] It is found in higher concentrations in female sebum compared to male sebum.[2] C24 dihydro Ceramide levels positively correlate with cytotoxicity in CCRF-CEM, MOLT-4, COG-LL-317h, and COG-LL-332h T cell acute lymphoblastic leukemia (ALL) cell lines.[4] Levels of C24 dihydro ceramide are increased by 149.49-fold in dihydroceramide desaturase 1 (DEGS1) knockdown UM-SCC-22A human head and neck squamous carcinoma cells in vitro.[4] C24 dihydro Ceramide levels are also increased in INS-1 β-cells incubated with glucose and palmitate.[5]

Barecetamab (ISU-104), a fully human anti-ErbB3 monoclonal antibody, is utilized in researching recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) [1].

Cevimeline, a parasympathomimetic and muscarinic agonist, affects M1 and M3 receptors. Cevimeline has been shown to treat dry mouth and Sj gren's syndrome. It is also used to reduce Xerostomia symptoms and increase salivary flow in head and neck cancer survivors after radiotherapy.

Tamsulosin ((R)-(-)-YM12617 free base) is an alpha1A adrenergic receptor antagonist used for the symptomatic treatment of benign prostatic hyperplasia (BPH). It treats difficulty urinating, a common symptom of an enlarged prostate, by relaxing the neck muscles of the bladder and muscle fibers in the prostate itself, easing urination.

TRPV1 Activator-1 (Compound 8), a capsaicin analog featuring a modified neck structure, specifically interacts with the T551 residue [1].

Edatrexate (CGP 30694), also known as 10-Ethyl-10-deazaaminopterin, is an analog of Methotrexate that demonstrates antitumor activity against Methotrexate-resistant tumors. This antifolate antimetabolite is utilized in research related to non-small-cell lung cancer, breast cancer, non-Hodgkin's lymphoma, and head and neck cancer [1] [2].

JH-XIV-68-3 is a selective inhibitor of the DYRK1A B macrocycle, acting specifically on DYRK1A and DYRK1B in biochemical and cellular assays, and exhibiting antitumor effects in head and neck squamous cell carcinoma (HNSCC) cell lines.

PD 173955-Analog1 is a potent c-Src inhibitor known to have activity against a variety of cancers including colon, lung, head and neck carcinoma.

Lirilumab (IPH2102) is an antibody against the lethal immunoglobulin-like receptor antibody KIR2D with antitumor activity that enhances the anti-HPV + cervical cancer activity of natural killer cells through VAV1-dependent NF-κB deinhibition. It can be used to study leukemia, head and neck squamous cell carcinoma (SCCHN).

HN-1, a 12-mer peptide with specificity for head and neck squamous cell carcinoma (HNSCC), penetrates tumor tissue and facilitates the translocation of agents across cell membranes [1].

JH-XVII-10 is a selective, orally active and potent inhibitor of DYRK1A (IC50: 3 nM) and DYRK1B (IC50: 5 nM).JH-XVII-10 exhibits antitumor effects in squamous cell carcinoma of the neck (HNSCC) cell lines.

Casein Kinase inhibitor A51 is an orally active casein kinase 1α (CK1α) inhibitor with anticancer activity that induces apoptosis in leukemia cells, and may be used in the study of neck cancers, acute myeloid leukemia, breast and prostate cancers.

Onvatilimab (JNJ-61610588) is a human IgG1 κ-anti-Vista (T-cell-activated V-domain Ig inhibitor) monoclonal antibody with antitumor activity, potentially used for treating advanced head and neck cancers.

Se-Methylselenocysteine (Se-MSC) is a potent chemopreventive agent in many test systems and has been shown to inhibit tumor promotion and induce apoptosis.

Tectol has anti-plasmodial activity, it as a moderately active growth inhibitor with an IC50 3.44±0.20μM. It exhibited significant activity against human leukemia cell lines HL60 and CEM. Tectol may cause itchy dermatitis, the dermatitis appeared on the n

EGFR-IN-59 is an EGFR inhibitor with an IC50 value of 190 nM and an all-time apoptosis inducer. EGFR-IN-59 exhibited cytotoxicity against a non-small lung cancer cell line (A549) and normal lung fibroblasts (WI38) with IC50s of 8.62 and 52.6 μM, respectively. EGFR-IN-59 EGFR-IN-59 can be used to study a variety of cancers including non-small cell lung cancer (NSCLC), head and neck cancer, breast cancer and colorectal cancer.

Topoisomerase II inhibitor 15 (compound 2g) is a potent inducer of apoptosis, demonstrating high selectivity for head and neck tumors [1].

BQ-3020 ammonium, a selective endothelin receptor (ET B receptor) agonist, demonstrates inhibition of [125 I] ET-1 binding to ET B receptors with an IC50 of 0.2 nM and induces vasoconstriction in rabbit pulmonary arteries. Additionally, it promotes relaxation of the pig urinary bladder neck, rendering it useful for research into cardiovascular diseases [1] [2].